Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences (NASDAQ: ANIX) announced the second patient has been treated in the fifth cohort of its Phase 1 clinical trial for recurrent ovarian cancer. The trial, conducted at Moffitt Cancer Center, evaluates a novel FSHR-targeted CAR-T therapy. Patients in the fifth cohort receive 1×10⁷ CAR-positive cells/kg following lymphodepletion. No dose-limiting toxicities have been observed, and multiple patients have survived over a year, with one surpassing two years.
How this was made
The 30-second read
Why it matters
The announcement provides the first public evidence of durable responses in this trial, likely to generate short‑term buying interest in ANIX.
Market read
Early positive safety and durability data could lift ANIX stock and benefit related CAR‑T oncology stocks.
What to watch
Trial still early; no efficacy endpoints reported and sample size remains very small.
Background
Anixa Biosciences (NASDAQ: ANIX) announced treatment of its second patient in Cohort 5 of a Phase 1 FSHR‑targeted CAR‑T trial for recurrent ovarian cancer, noting >1‑year survivals and no dose‑limiting toxicities.
Ticker impact
Second patient treated in Phase 1 ovarian cancer CAR-T trial; no dose‑limiting toxicities and multiple patients survived >1 year.
potential upside as market prices in promising early efficacy and safety signals
First disclosure of multi‑year survivals and lack of toxicities in the highest dose cohort; rare positive signal for a micro‑cap biotech.
Market effects
May lift sentiment for other CAR‑T and ovarian‑cancer biotech peers.
Limited to US biotech sector; no broader regional effect.
Modest global relevance; primarily impacts niche oncology investors.
Counterpoint
Early‑stage data may be over‑hyped; survivals could reflect patient selection rather than drug efficacy.
Key entities
- companyAnixa Biosciences, Inc.
Clinical‑stage biotech developing FSHR‑targeted CAR‑T therapy.
- institutionMoffitt Cancer Center
Site conducting the Phase 1 trial.
